Replimune Group (NASDAQ:REPL) Stock Price Down 5.3% – Should You Sell?

Replimune Group, Inc. (NASDAQ:REPL) shares dropped 5.3% on Thursday . The company traded as low as $15.12 and last traded at $15.14. Approximately 763,180 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 4,804,738 shares. The stock had previously closed at $15.98.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on REPL shares. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a report on Friday, August 7th. JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target on the stock in a research report on Tuesday, June 30th. Finally, Wall Street Zen raised Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

Replimune Group Stock Performance

The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23. The business has a 50 day moving average price of $12.10 and a two-hundred day moving average price of $8.51. The company has a market cap of $1.42 billion, a P/E ratio of -4.80 and a beta of 0.94.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, sell-side analysts anticipate that Replimune Group, Inc. will post -2.81 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Emily Luisa Hill sold 9,256 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $14.28, for a total transaction of $132,175.68. Following the completion of the transaction, the chief financial officer owned 215,852 shares in the company, valued at $3,082,366.56. This represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $98,987.04. Following the completion of the transaction, the chief accounting officer owned 99,425 shares of the company’s stock, valued at $1,289,542.25. This trade represents a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 79,124 shares of company stock valued at $1,038,364 over the last three months. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of large investors have recently modified their holdings of REPL. BlackRock Inc. purchased a new position in shares of Replimune Group during the 2nd quarter worth approximately $99,171,000. Balyasny Asset Management L.P. lifted its stake in shares of Replimune Group by 507.4% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after purchasing an additional 2,195,448 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of Replimune Group in the 4th quarter valued at approximately $17,568,000. Commodore Capital LP bought a new stake in shares of Replimune Group during the fourth quarter valued at approximately $13,851,000. Finally, EcoR1 Capital LLC bought a new stake in shares of Replimune Group during the first quarter valued at approximately $7,650,000. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.